By Michael Dabaie

 

Kaleido Biosciences Inc. (KLDO) said it initiated a research collaboration with Johnson & Johnson's (JNJ) Janssen Pharmaceutical Cos.

The companies will look at the potential for Kaleido's Microbiome Metabolic Therapies, or MMTs, to prevent the onset of childhood allergy and other atopic, immune and metabolic conditions. The agreement was facilitated by Johnson & Johnson Innovation, Kaleido said.

A primary focus of the research will be to utilize Kaleido's screening platform to identify MMTs candidates that support the growth of specific beneficial microbes. These MMTs will then be further evaluated for their ability to prevent atopic conditions such as infant allergy, Kaleido said.

 

Write to Michael Dabaie at michael.dabaie@wsj.com

 

(END) Dow Jones Newswires

January 09, 2020 08:43 ET (13:43 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Sep 2020 to Oct 2020 Click Here for more Johnson and Johnson Charts.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Oct 2019 to Oct 2020 Click Here for more Johnson and Johnson Charts.